Yago Garitaonaindia, Translational Research Fellow at CCIT-DK – National Center for Cancer Immune Therapy of Denmark, shared a post on Linkedin:
“Pancreatic cancer. Second line. HR 0.40.
Daraxonrasib (Revolution Medicines) just reported Phase 3 results in previously treated metastatic pancreatic cancer: median OS 13.2 vs 6.7 months with chemotherapy. HR 0.40. p<0.0001.
Why does this matter beyond pancreas? KRAS is on of the most frequently mutated oncogene in human cancer – present in approx. 20% of all solid tumours, including 30% of lung adenocarcinomas and >80% of PDAC, among others. Targeting it broadly, not just G12C, has been the goal for decades.
Daraxonrasib is a multi-selective RAS(ON) inhibitor. Different mechanism, broader target, different resistance profile expected.
Full data at ASCO 2026 (including toxicity and subgroups). Topline only for now – still need to see the complete safety and efficacy profile.
Looking forward to seeing its activity in NSCLC.”
Title: Emerging landscape of KRAS inhibitors in cancer treatment
Authors: Jakob M. Riedl, Hiroyuki Matsubara, Reid McNeil, Parasvi S. Patel, Ferran Fece de la Cruz, Doga C. Gulhan, Ryan B. Corcoran
Read the Full Article.
